정밀 게놈 검사 시장 보고서(2025년)
Precision Genomic Testing Global Market Report 2025
상품코드 : 1811009
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

정밀 게놈 검사 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 11.4%로 231억 1,000만 달러로 성장합니다. 예측 기간의 성장은 정밀 종양학 솔루션에 대한 수요 증가, 희귀질환 진단에 대한 관심 증가, 집단 유전체학 구상에 대한 투자 확대, 멀티오믹스 접근법 활용 확대, 비침습적 산전 검사에 대한 수요 증가에 기인하는 것으로 분석됩니다. 이 기간 중 예상되는 주요 동향으로는 차세대 시퀀싱 기술의 발전, 액체생검 기술의 혁신, 유전체 분석에 인공지능의 통합, 멀티오믹스 데이터 분석의 개선, 소비자 직접 유전자 검사 모델의 진화 등을 들 수 있습니다.

유전성 질환의 유병률 증가는 향후 수년간 정밀유전체검사 시장의 성장을 가속할 것으로 예측됩니다. 유전성 질환은 개인의 DNA 이상에 의해 발생하는 병으로 단일 유전자의 변이, 여러 유전자의 변이, 염색체의 구조적 또는 수치적 변화를 수반할 수 있습니다. 이러한 유전성 질환 증가는 산모의 연령이 높아지는 것이 주요 원인이며, 고령의 산모는 다운증후군과 같은 염색체 이상 자녀를 낳을 위험이 높기 때문입니다. 정밀 게놈 검사는 특정 유전자 변이를 확인함으로써 유전성 질환의 조기 발견과 정확한 진단을 가능하게 하고, 표적화된 개입과 맞춤 치료 계획을 지원합니다. 예를 들어 2025년 5월 영국에 본부를 둔 등록 자선단체인 진 피플스(Gene People)는 유전질환이 어린이 25명 중 1명에게 영향을 미치며, 영국에서는 240만 명 이상이 영향을 받고 있다고 보고했습니다. 또한 영국에서는 매년 약 3만 명의 신생아와 어린이가 유전병 진단을 받고 있습니다. 그 결과 유전성 질환의 발병률이 높아지면서 정밀유전체검사 시장의 성장에 박차를 가하고 있습니다.

정밀유전체검사 시장의 기업은 암의 조기 발견과 진단 정확도를 높이기 위해 초민감도 순환종양 DNA 분석 등 첨단 기술 개발에 집중하고 있습니다. 이러한 검사법은 혈류에 존재하는 종양 유래 DNA의 미세한 단편을 식별할 수 있으며, 암과 관련된 유전자 변이를 보다 조기에, 보다 정확하게 검출할 수 있습니다. 예를 들어 2025년 4월 미국의 임상 유전자 검사 회사인 Natera Inc.는 초민감도 Signatera 유전체 분자 잔존 병변 검사를 출시했습니다. 이 검사는 환자의 종양 DNA와 일치하는 정상 DNA의 전장유전체 시퀀싱을 적용하여 개인별 맞춤 분석법을 만들어 100만분의 1이라는 극히 낮은 농도의 순환 종양 DNA를 검출할 수 있습니다. 이러한 높은 민감도는 암의 재발을 조기에 발견할 수 있으며, 여러 암종에 대한 치료 계획과 환자 치료를 개선할 수 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Precision genomic testing involves the use of advanced genetic analysis to detect specific DNA variations or mutations that impact an individual's risk of disease, diagnosis, prognosis, or treatment response. This approach supports personalized healthcare by enabling tailored prevention strategies, therapeutic interventions, and drug selection based on a person's unique genetic profile.

The key products and services in precision genomic testing include consumables, equipment, and services. Consumables are items intended for single or repeated use and are depleted through routine procedures, examples include laboratory reagents and medical supplies. The testing employs a variety of advanced technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray technology, Sanger sequencing, and CRISPR-associated systems. It is applied across multiple areas, including oncology, cardiovascular diseases, neurological disorders, reproductive health, rare diseases, and more. End users include hospitals and clinics, diagnostic laboratories, research and academic institutions, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The precision genomic testing market research report is one of a series of new reports from The Business Research Company that provides precision genomic testing market statistics, including precision genomic testing global market size, regional shares, competitors with precision genomic testing market share, detailed precision genomic testing market segments, market trends and opportunities, and any further data you may need to thrive in the precision genomic testing industry. The precision genomic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The precision genomic testing market size has grown rapidly in recent years. It will grow from $13.44 billion in 2024 to $15.00 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. Growth in the historic period can be attributed to the increasing availability of direct-to-consumer genetic testing, rising collaborations between pharmaceutical and diagnostic companies, a heightened focus on preventive healthcare, greater adoption of companion diagnostics, and growing awareness of the importance of early disease detection.

The precision genomic testing market size is expected to see rapid growth in the next few years. It will grow to $23.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. Growth in the forecast period can be attributed to the rising demand for precision oncology solutions, increased focus on rare disease diagnostics, growing investment in population genomics initiatives, expanded use of multi-omics approaches, and the rising demand for non-invasive prenatal testing. Key trends expected during this period include advancements in next-generation sequencing technologies, innovations in liquid biopsy techniques, integration of artificial intelligence in genomic analysis, improvements in multi-omics data interpretation, and the evolution of direct-to-consumer genetic testing models.

The increasing prevalence of genetic disorders is anticipated to drive the growth of the precision genomic testing market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual's DNA, which may involve mutations in a single gene, multiple genes, or structural or numerical changes in chromosomes. This rise in genetic disorders is largely attributed to the increasing maternal age, as older mothers face a higher risk of having children with chromosomal abnormalities, such as Down syndrome. Precision genomic testing allows for early detection and accurate diagnosis of genetic disorders by identifying specific genetic mutations, which supports targeted interventions and personalized treatment plans. For example, in May 2025, Gene People, a UK-based registered charity, reported that genetic conditions affect approximately 1 in 25 children, impacting over 2.4 million individuals in the UK. Additionally, around 30,000 newborns and children are diagnosed with a genetic condition each year in the UK. As a result, the rising incidence of genetic disorders is fueling the growth of the precision genomic testing market.

Companies in the precision genomic testing market are focusing on the development of advanced technologies, such as ultra-sensitive circulating tumor DNA assays, to improve early cancer detection and diagnostic accuracy. These assays are capable of identifying minute fragments of tumor-derived DNA present in the bloodstream, which enables earlier and more precise detection of genetic mutations associated with cancer. For instance, in April 2025, Natera Inc., a US-based clinical genetic testing company, launched the ultra-sensitive Signatera genome molecular residual disease test. This test applies whole genome sequencing of both the patient's tumor and matched normal DNA to create a personalized assay, enabling detection of circulating tumor DNA at extremely low concentrations-down to 1 part per million. Such high sensitivity allows for earlier detection of cancer recurrence, improving treatment planning and patient care across multiple cancer types.

In November 2022, Myriad Genetics Inc., a US-based healthcare company, acquired Gateway Genomics LLC for $67.5 million. This acquisition was aimed at strengthening Myriad Genetics' women's health portfolio by expanding into the early prenatal testing segment. The addition of Gateway Genomics' SneakPeek early gender DNA test broadens Myriad's offerings in the consumer genetic testing space. Gateway Genomics LLC, based in the US, specializes in the development of genetic-based tests for consumers, particularly focused on early prenatal applications.

Major players in the precision genomic testing market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Ambry Genetics Corporation, Color Health Inc., Pacific Biosciences, Eurofins Genomics LLC, and Precision Genetics.

North America was the largest region in the precision genomic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in precision genomic testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the precision genomic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The precision genomic testing market consists of revenues earned by entities by providing services such as gene panel testing, whole genome and exome analysis, pharmacogenomics testing, cancer genomics profiling, hereditary disease screening, and bioinformatics-driven interpretation of genetic data. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision genomic testing market also includes sales of hybridization buffers and enzymes, targeted gene panels, library preparation kits, genomic data compression tools, and rare mutation detection kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Precision Genomic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on precision genomic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for precision genomic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The precision genomic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Precision Genomic Testing Market Characteristics

3. Precision Genomic Testing Market Trends And Strategies

4. Precision Genomic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Precision Genomic Testing Growth Analysis And Strategic Analysis Framework

6. Precision Genomic Testing Market Segmentation

7. Precision Genomic Testing Market Regional And Country Analysis

8. Asia-Pacific Precision Genomic Testing Market

9. China Precision Genomic Testing Market

10. India Precision Genomic Testing Market

11. Japan Precision Genomic Testing Market

12. Australia Precision Genomic Testing Market

13. Indonesia Precision Genomic Testing Market

14. South Korea Precision Genomic Testing Market

15. Western Europe Precision Genomic Testing Market

16. UK Precision Genomic Testing Market

17. Germany Precision Genomic Testing Market

18. France Precision Genomic Testing Market

19. Italy Precision Genomic Testing Market

20. Spain Precision Genomic Testing Market

21. Eastern Europe Precision Genomic Testing Market

22. Russia Precision Genomic Testing Market

23. North America Precision Genomic Testing Market

24. USA Precision Genomic Testing Market

25. Canada Precision Genomic Testing Market

26. South America Precision Genomic Testing Market

27. Brazil Precision Genomic Testing Market

28. Middle East Precision Genomic Testing Market

29. Africa Precision Genomic Testing Market

30. Precision Genomic Testing Market Competitive Landscape And Company Profiles

31. Precision Genomic Testing Market Other Major And Innovative Companies

32. Global Precision Genomic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Precision Genomic Testing Market

34. Recent Developments In The Precision Genomic Testing Market

35. Precision Genomic Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기